Relay Therapeutics (RLAY) Return on Sales (2021 - 2025)
Historic Return on Sales for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to 35.52%.
- Relay Therapeutics' Return on Sales fell 10200.0% to 35.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.52%, marking a year-over-year decrease of 10200.0%. This contributed to the annual value of 33.75% for FY2024, which is 203600.0% down from last year.
- Relay Therapeutics' Return on Sales amounted to 35.52% in Q3 2025, which was down 10200.0% from 103.02% recorded in Q2 2025.
- Relay Therapeutics' Return on Sales' 5-year high stood at 83496.0% during Q4 2023, with a 5-year trough of 827.66% in Q2 2023.
- Moreover, its 5-year median value for Return on Sales was 91.34% (2021), whereas its average is 4245.31%.
- In the last 5 years, Relay Therapeutics' Return on Sales soared by 837627200bps in 2023 and then crashed by -835297500bps in 2024.
- Quarter analysis of 5 years shows Relay Therapeutics' Return on Sales stood at 118.97% in 2021, then tumbled by -124bps to 266.72% in 2022, then soared by 31405bps to 83496.0% in 2023, then plummeted by -100bps to 33.75% in 2024, then dropped by -5bps to 35.52% in 2025.
- Its Return on Sales was 35.52% in Q3 2025, compared to 103.02% in Q2 2025 and 10.03% in Q1 2025.